IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC, MYLAN PHARMACEUTICALS INC., BRECKENRIDGE PHARMACEUTICAL, INC., and ALEMBIC PHARMACEUTICALS, LTD., Petitioners,

V.

RESEARCH CORPORATION TECHNOLOGIES, INC., Patent Owner.

Case No. IPR2016-00204¹
Patent No. RE 38,551

PATENT OWNER'S UPDATED EXHIBIT LIST



¹ Case IPR2016-01101, Case IPR2016-01242, and Case IPR2016-01245 have been joined with this proceeding.

IPR2016-00204 029819.0100-US03


LIST OF EXHIBITS

Exhibit	Description
2001	Richard H. Mattson, Efficacy and Adverse Effects of Established and New Antiepileptic Drugs, 36 (Suppl. 2) Epilepsia S13-S26 (1995).
2002	Richard H. Mattson, <i>Drug Treatment of Uncontrolled Seizures</i> , in Surgical Treatment of Epilepsy 29-35 (William H. Theodore ed., 1992).
2003	FDA Approved Labeling Text dated August 27, 2012 for FELBATOL® (felbamate), available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s 027lbl.pdf (last visited Feb. 2, 2016).
2004	Judith D. Conley & Harold Kohn, Functionalized DL-Amino Acid Derivatives. Potent New Agents for the Treatment of Epilepsy, 30 J. Med. Chem. 567-574 (1987).
2005	U.S. Provisional Patent Application No. 60/013,522.
2006	Bialer et al., Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI), 51 Epilepsy Res. 31-71 (2002).
2007	Jerry March, Advanced Organic Chemistry 94-96 (4th ed. 1992).
2008	Decision Denying Institution of <i>Inter Partes</i> Review, IPR2014-01126, Paper 22.
2009	Curriculum Vitae of Dr. Farrokh Mistree, September 2014.
2010	Marcy Barge & W.T. Ingram, <i>Inverse Limits on [0,1] Using Logistic Bonding Maps</i> , 72 Topology and its Applications 159-72 (1996).
2011	Jack McBryde Jr., Inverse Limits on Arcs Using Certain Logistic Maps as Bonding Maps, Master's Thesis, University of Houston, (1987).
2012	Trial Testimony of Dr. Clayton Heathcock, <i>UCB</i> , <i>Inc.</i> , <i>et al.</i> , <i>v. Accord Healthcare</i> , <i>Inc.</i> , <i>et. al.</i> , No. 13-1206-LPS (D. Del., Nov. 9, 2015).
2013	FDA Approved Labeling Text dated July 9, 2015 for VIMPAT® (lacosamide), available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022253s 030,022254s022,022255s016lbl.pdf (last visited Feb. 2, 2016).
2014	Wolfgang Löscher & Dieter Schmidt, Strategies in Antiepileptic Drug Development: Is Rational Drug Design Superior to Random Screening and Structural Variation?, 17 Epilepsy Research 95-134 (1994).




IPR2016-00204

Exhibit	Description
2015	Michael A. Rogawski & Roger J. Porter, Antiepileptic Drugs:
	Pharmacological Mechanisms and Clinical Efficacy with
	Consideration of Promising Developmental Stage Compounds,
	42(3) Pharmacological Reviews 223-86 (1990).
2016	John M. Pellock, Standard Approach to Antiepileptic Drug
	Treatment in the United States 35 (Suppl. 4) Epilepsia S11-S18
	(1994).
2017	Approval Listing dated December 27, 1994 for lamotrigine,
	Approved Drug Products with Therapeutic Equivalence Evaluations
	(Electronic Orange Book),
	http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Ap
	pl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016).
2018	The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915,
	998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330,
	1654 (Susan Budavari et al. eds., 12th ed. 1996).
2019	Approval Listing dated August 5, 1996 for fosphenytoin sodium,
	Approved Drug Products with Therapeutic Equivalence Evaluations
	(Electronic Orange Book),
	http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Ap
2020	pl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016).
2020	FDA Approved Labeling Text dated January 2014 for CEREBYX®
	(fosphenytoin sodium injection), available at
	http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020450s
2021	023lbl.pdf (last visited Feb. 2, 2016).
2021	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Beclamide,
	http://chem.sis.nlm.nih.gov/chemidplus/rn/501-68-8 (last visited
2022	Feb. 2, 2016).
2022	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Phenacemide,
	http://chem.sis.nlm.nih.gov/chemidplus/rn/63-98-9 (last visited Feb.
2023	2, 2016).
	ChemIDPlus, Toxnet, U.S. Nat'l Library of Medicine, Valproic
	acid, http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1 (last visited
2024	Feb. 2, 2016). Portfolio – Mont Alta Canital
402 4 	Portfolio – Mont Alto Capital, http://www.montaltagonital.gom/portfolio/ (last visited Esh. 22)
	http://www.montaltocapital.com/portfolio/ (last visited Feb. 23,
	2016).




IPR2016-00204 029819.0100-US03

Exhibit	Description
2025	Trial Transcript, UCB, Inc., et al., v. Accord Healthcare, Inc., et. al.,
	No. 13-1206-LPS (D. Del., Nov. 9-13, 2015). (served, but not filed,
	March 17, 2016)
2026	PTAB Telephonic Conference Transcript, IPR2016-00204 (March
	8, 2016).
2027	PTAB Telephonic Conference Transcript, IPR2016-00204 (April 4,
	2016).
2028	PTAB Email to Counsel of Record (January 12, 2016).
2029	U.S. Provisional Patent Application No. 60/013,522 file history.
	(served, but not filed, June 21, 2016) (filed and served, August 15,
	2016)
2030	IPR2014-01126 Petition for <i>Inter Partes</i> Review of U.S. Patent No.
	RE 38,551 (July 10, 2014)
2031	PTAB Telephonic Conference Transcript, IPR2016-00204 (June 22,
	2016).
2032	M. Dowd Email to A. Reister (March 31, 2016)
2033	M. Dowd Email to A. Reister (April 13, 2016)
2034	M. Dowd Email to A. Reister (May 26, 2016)
2035	Transcript, Deposition of Binghe Wang, Ph.D. (July 18, 2016).
2036	Declaration of William R. Roush, Ph.D., in Support of Patent Owner
	Response Pursuant to 37 C.F.R. §42.120.
2037	William R. Roush, Ph.D. curriculum vitae.
2038	Declaration of Carl W. Bazil, M.D., Ph.D., in Support of Patent
	Owner Response Pursuant to 37 C.F.R. §42.120.
2039	Carl W. Bazil, M.D., Ph.D. curriculum vitae.
2040	Jerry March, Advanced Organic Chemistry (3rd ed. 1985) excerpts.
2041	Jean Jacques et al., Enantiomers, Racemates, and Resolutions
	(Reprint Ed. 1991) excerpt.
2042	Lacosamide, SciFinder® Scholar, version 205; Chemical Abstracts
	Service: Columbus, OH.
2043	J. Hyttel et al., The pharmacological effect of citalopram resides in
	the (S)-(+)-enantiomer, 88(2) J. Neural Transm. 157–60 (1992).
2044	Seizure Medication List, Epilepsy Foundation, at
	http://www.epilepsy.com/learn/treating-seizures-and-
	epilepsy/seizure-and-epilepsy-medicines/seizure-medication-list
	(last accessed July 25, 2016)



IPR2016-00204 029819.0100-US03

Exhibit	Description
2045	Signe Stórustovu et al., R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at
2046	the serotonin transporter, 142(1) Br. J. Pharmacol. 172–80 (2004).
2046	Overview of the Drug Development Process, available at http://lillytrials.com/docs/education.html (last accessed August 3, 2016).
2047	Center for Drug Evaluation and Research, 2011 Novel New Drugs (Jan. 2012).
2048	Sunil S. Jambhekar, <i>Biopharmaceutical Properties of Drug Substances</i> , <i>in</i> Principles of Medicinal Chemistry (William O. Foye <i>et al.</i> , eds., 4th ed. 1995).
2049	Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, Chapter 2 (2nd ed. 2004).
2050	F. Raymond Salemme et al., Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery, 5(3) Structure 319–24 (1997)
2051	Hugo Kubinyi, <i>Combinatorial and computational approaches in structure-based drug design</i> , 1(1) Curr. Opinion Drug Discov. Develop. 16–27 (1998).
2052	Harold Kohn & Judith D. Conley, <i>New antiepileptic agents</i> , 24(3) Chemistry in Britain 231–34 (1988).
2053	Harold Kohn et al., Marked stereospecificity in a new class of anticonvulsants, 457 Brain Res. 371–75 (1988).
2054	Our Mission, Epilepsy Foundation, at http://www.epilepsy.com/dare-defy-seizures/our-mission (last visited July 25, 2016)
2055	Harold Kohn et al., Anticonvulsant Properties of N-Substituted α,α-Diamino Acid Derivatives, 83 J. Pharmaceutical Sci. 689 (May 1994)
2056	Patrick Bardel et al., Synthesis and Anticonvulsant Activities of α-Acetamido-N-benzylacetamide Derivatives Containing an Electron-Deficient α-Heteroaromatic Substituent, 37(26) J. Med. Chem. 4567–71 (1994)
2057	M. C. Walker & P. N. Patsalos, <i>Clinical Pharmakokinetics of New Antiepileptic Drugs</i> , 67(3) Pharmacol. Ther. 351–84 (1995).
2058	H. Steve White et al., General Principles: Experimental Selection, Quantification, and Evaluation of Antiepileptic Drugs, in Antiepileptic Drugs (René H. Levy et al., eds., 4th ed. 1995).



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

